OBI Pharma (ROCO:4174) FCF Margin % : -3,583.74% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. OBI Pharma's Free Cash Flow for the three months ended in Dec. 2024 was NT$-413.85 Mil. OBI Pharma's Revenue for the three months ended in Dec. 2024 was NT$11.55 Mil. Therefore, OBI Pharma's FCF Margin % for the quarter that ended in Dec. 2024 was -3,583.74%.

As of today, OBI Pharma's current FCF Yield % is -19.55%.

The historical rank and industry rank for OBI Pharma's FCF Margin % or its related term are showing as below:

ROCO:4174' s FCF Margin % Range Over the Past 10 Years
Min: -334916.22 Med: -6875.62 Max: -1107.36
Current: -3116.04

During the past 13 years, the highest FCF Margin % of OBI Pharma was -1107.36%. The lowest was -334916.22%. And the median was -6875.62%.

ROCO:4174's FCF Margin % is ranked worse than
86.79% of 999 companies
in the Biotechnology industry
Industry Median: -120.51 vs ROCO:4174: -3116.04

OBI Pharma FCF Margin % Historical Data

The historical data trend for OBI Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OBI Pharma FCF Margin % Chart

OBI Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-1,274.14

-6,976.68

-40,761.18

-4,238.71

-3,116.04

OBI Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-2,476.66	-6,209.34	-2,690.63	-2,003.34	-3,583.74

Competitive Comparison of OBI Pharma's FCF Margin %

For the Biotechnology subindustry, OBI Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OBI Pharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OBI Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where OBI Pharma's FCF Margin % falls into.

Save Embed

;

Save Embed

;

OBI Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

OBI Pharma's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-1953.07	/	62.678
	=	-3,116.04 %

OBI Pharma's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-413.85	/	11.548
	=	-3,583.74 %

OBI Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of OBI Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

OBI Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 508, Section. 7, Zhongxiao East Road, 6th Floor, Nangang District, Taipei, TWN, 115011

Website

https://www.obipharma.com

OBI Pharma Inc is a clinical-stage oncology company. It focuses on research and development for cancer therapies and aims to develop ground-breaking drugs. The core value lies in its passion to develop and deliver a portfolio of antibody-drug conjugates (ADCs) drugs for patients, in addition to its Globo H active immunotherapy. Its portfolio includes a spectrum of cancer targets, such as TROP2, Nectin-4, HER2, and other potential targets. These ADCs are built based on two distinct ADC technology platforms, with different characteristics. It offers a plug-and-play advantage through a specialized site-specific conjugation using a proprietary enzyme. Its segments are the anti-cancer new drug; bispecific monoclonal antibody new drug; botulinum toxin new drug; and CDMO segment.

OBI Pharma Headlines

No Headlines